Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Arcturus Therapeutics Holdings Inc

ARCT
Current price
29.78 USD -0.72 USD (-2.36%)
Last closed 30.5 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 734 160 896 USD
Yield for 12 month +11.41 %
1Y
3Y
5Y
10Y
15Y
ARCT
21.11.2021 - 28.11.2021

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Address: 10628 Science Center Drive, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

67.5 USD

P/E ratio

Dividend Yield

Current Year

+157 748 000 USD

Last Year

+205 755 000 USD

Current Quarter

+32 598 000 USD

Last Quarter

+28 212 000 USD

Current Year

+154 791 000 USD

Last Year

+62 704 000 USD

Current Quarter

+38 012 000 USD

Last Quarter

+27 397 000 USD

Key Figures ARCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -119 289 000 USD
Operating Margin TTM -77.9 %
PE Ratio
Return On Assets TTM -17.22 %
PEG Ratio
Return On Equity TTM -36.17 %
Wall Street Target Price 67.5 USD
Revenue TTM 124 526 000 USD
Book Value 9.81 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -52.7 %
Dividend Yield
Gross Profit TTM 62 948 000 USD
Earnings per share -4.03 USD
Diluted Eps TTM -4.03 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -86.16 %

Dividend Analytics ARCT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:7
Payout Ratio
Last Split Date 16.11.2017
Dividend Date 16.11.2017

Stock Valuation ARCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 2.4777
Enterprise Value Revenue 3.541
Price Sales TTM 4.9103
Enterprise Value EBITDA -23.1146
Price Book MRQ 2.9456

Financials ARCT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARCT

For 52 weeks

17.52 USD 43.81 USD
50 Day MA 31.53 USD
Shares Short Prior Month 4 613 132
200 Day MA 29.52 USD
Short Ratio 10.32
Shares Short 4 916 314
Short Percent 28.72 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

420.21 USD Microsoft Corporation -1.96 (-0.46%)
Detailed analytics

ETF funds


S

SX7EEX

14.76 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.03 (+0.2%)
Detailed analytics

Metals


Gold

2414.65 USD Gold +37.17 (+1.56%)
Detailed analytics